House overwhelmingly passes anti-opioid legislation

In a 396-14 vote, the House of Representatives passed the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, or  H.R. 6—bipartisan opioid legislation that aims to curb drug abuse. 

Sponsored by Greg Walden, R-Oregon, the package of legislation contains more than 50 individually approved bills to address what President Donald Trump has called a health emergency.

In a Twitter post, House Speaker Paul Ryan, R-Wisconsin, said the SUPPORT bill will fight the opioid crisis by advancing treatment and recovery programs, improving prevention efforts, providing resources to communities and fighting drugs like Fentanyl.  

The legislation calls for a review of current opioid prescriptions, development and usage of non-addictive painkillers, making a patient’s addiction history as part of their medical records to prevent relapse and reducing the trafficking of Chinese fentanyl into the country. Additionally, the legislation will expand Medicare and Medicaid-related services to combat drug abuse. 

“This is a big deal in the fight against the largest public health crisis in our country,” said Ryan, while addressing the House.

Passage of the legislation was also applauded by the White House press secretary Sarah Huckabee Sanders.

“These necessary bills will help save American lives through prevention and education, treatment and recovery, and law enforcement and interdiction,” Sanders said. “We look forward to continuing our work with Congress on a problem that affects everyone and that should be solved by everyone.” 

Opposition votes came from 13 Republicans and a lone Democrat. The legislation is now headed to the Senate for review and passage.

""

As a senior news writer for TriMed, Subrata covers cardiology, clinical innovation and healthcare business. She has a master’s degree in communication management and 12 years of experience in journalism and public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.